CCA	cholangiocarcinoma
iCCA	intrahepatic cholangiocarcinoma
pCCA	perihilar cholangiocarcinoma
dCCA	distal cholangiocarcinoma
eCCA	extrahepatic cholangiocarcinoma
FGFR	fibroblast growth factor receptor
FGF	fibroblast growth factor
TK	tyrosine kinase
TKI	tyrosine kinase inhibitor
FDA	Food and Drug Administration
IDH1	Isocitrate dehydrogenase 1
ARID1A/ARID1B	AT-Rich Interaction Domain 1A/1B
BAP1 BRCA1	Associated Protein 1
TP53	tumour protein p53
RAS	rat sarcoma viral proto-oncogene
PTEN	Phosphatase And Tensin Homolog
APC	Regulator Of WNT Signalling Pathway
EPHA2	Epithelial Cell Receptor Protein Tyrosine Kinase A2
PRKACA/PRKACB	Protein Kinase CAMP-Activated Catalytic Subunit Alpha/Beta
ELF3 E74	Like ETS Transcription Factor 3
PD-1/PD-L1	Programmed cell death protein 1/Programmed death-ligand 1
ERBB2	Erb-B2 Receptor Tyrosine Kinase 2
PI3K	phosphoinositide 3-kinase
AKT	kinases protein kinase B family
mTOR	Mammalian target of rapamycin
PLCγ	phospholipase C gamma
DAG	dystroglycan
PKC	protein kinase C
RAF	rapidly accelerated fibrosarcoma kinase
MEK	Mitogen-activated protein kinase kinase
MAPK	Mitogen activated protein kinase
JAK	kinase Janus kinase
STAT	signal transducer and activator of transcription
IP3	inositol trisphosphate
BICC1	Protein Bicaudal C Homolog 1
PPHLN1	Periphilin 1
TACC3	Transforming Acidic Coiled-Coil Containing Protein 3
MGEA5	meningioma expressed antigen 5
RET	Ret Proto-Oncogene
VEGFR1	Vascular endothelial growth factor receptor 1
DDR DNA	damage response and repair gene
CDKN2A/B	cyclin-dependent kinase inhibitor 2A/B
PBRM1	Polybromo 1 gene
cfDNA	cell-free circulating tumour DNA
siRNA	small interfering RNA
OS	overall survival
DFS	disease-free survival
ORR	overall response rate
PFS	progression-free survival
SD	stable disease
PR	partial response
PD	progressed disease
DCR	disease control rate
TEAE	treatment-emergent adverse events
AE	adverse events